Devang

“The data points – be it WPI or the data on industrial production – show we are doing relatively well. Plus, we are in the third quarter earnings season and will probably get into the prime…

"Credit growth and consumption and capex– the Cs – will lead to the fourth C which is corporate profitability. We are on a different tangent altogether. Whether the Indian market also gets…

“Sun Pharma is not on my buy list. Companies like Syngene or MNC pharma companies or Dr Lal Path Lab comes to mind immediately, if one wants to get exposure to the healthcare space after…

“Generally, we can stay underweight on autos but we are monitoring this space for more trends which are emerging,” says Devang Mehta, Head-Equity Advisory, Centrum India. How are you looking…

In pharma, money right now is going towards MNC pharma companies or diagnostic companies or for that matter even hospital companies, says Devang Mehta, Head-Equity Advisory, Centrum Wealth…

During the peak of Covid-19’s second wave, health systems across the nation witnessed their critical resources rapidly getting overwhelmed by an increasing number of patients. It threatened…